• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹膜透析的新进展:生物相容性与持续流动腹膜透析。

What's new in peritoneal dialysis: biocompatibility and continuous flow peritoneal dialysis.

作者信息

Stigant Caroline E, Bargman Joanne M

机构信息

Department of Medicine, University of Toronto, Toronto General Hospital, Ontario, Canada.

出版信息

Curr Opin Nephrol Hypertens. 2002 Nov;11(6):597-602. doi: 10.1097/00041552-200211000-00005.

DOI:10.1097/00041552-200211000-00005
PMID:12394604
Abstract

PURPOSE OF REVIEW

This review examines recent developments in the understanding of the effect of conventional, bioincompatible peritoneal dialysis fluids on structural and functional changes in the peritoneal membrane. Emphasis is placed on the clinically relevant outcome of failure of long-term peritoneal dialysis. Therapeutic strategies to prevent technique failure, including the use of new peritoneal dialysis fluids and continuous flow peritoneal dialysis, are explored.

RECENT FINDINGS

Long-term (greater than 6 months) exposure to new peritoneal dialysis fluids with physiologic pH, lower lactate concentrations, or lower concentrations of glucose degradation products results in improved leukocyte cytokine release, ultrafiltration, and mesothelial cell mass, respectively. Continuous flow peritoneal dialysis allows efficient small molecule removal using dialysate with lower glucose concentration and possibly less glucose degradation products. Recent technical advances include creation of a double-lumen peritoneal dialysis catheter, and methods of monitoring intra-abdominal pressure and ultrafiltration.

SUMMARY

Though initial reports with biocompatible peritoneal dialysis fluids are promising, the efficacy of these new solutions in preventing long-term peritoneal dialysis failure is unproven. Conditions in which new peritoneal dialysis fluids may be beneficial are suggested. Continuous flow peritoneal dialysis requires substantial technical improvements before this technique can be widely accepted.

摘要

综述目的

本综述探讨了对传统生物不相容性腹膜透析液对腹膜结构和功能变化影响的最新认识进展。重点关注长期腹膜透析失败这一临床相关结局。探索了预防技术失败的治疗策略,包括使用新型腹膜透析液和持续非卧床腹膜透析。

最新发现

长期(超过6个月)暴露于生理pH值、较低乳酸浓度或较低葡萄糖降解产物浓度的新型腹膜透析液,分别可改善白细胞细胞因子释放、超滤和间皮细胞数量。持续非卧床腹膜透析使用较低葡萄糖浓度且可能葡萄糖降解产物较少的透析液可有效清除小分子物质。近期技术进展包括双腔腹膜透析导管的研发,以及监测腹腔内压力和超滤的方法。

总结

尽管关于生物相容性腹膜透析液的初步报告很有前景,但这些新溶液在预防长期腹膜透析失败方面的疗效尚未得到证实。提出了新型腹膜透析液可能有益的情况。在持续非卧床腹膜透析技术被广泛接受之前,需要进行大量技术改进。

相似文献

1
What's new in peritoneal dialysis: biocompatibility and continuous flow peritoneal dialysis.腹膜透析的新进展:生物相容性与持续流动腹膜透析。
Curr Opin Nephrol Hypertens. 2002 Nov;11(6):597-602. doi: 10.1097/00041552-200211000-00005.
2
Recent concepts in the molecular biology of the peritoneal membrane - implications for more biocompatible dialysis solutions.腹膜分子生物学的最新概念——对更具生物相容性透析液的启示
Blood Purif. 2003;21(1):14-23. doi: 10.1159/000067867.
3
[Influence of new dialysis solutions on clinical results in patients treated with peritoneal dialysis].[新型透析液对接受腹膜透析治疗患者临床结果的影响]
Wien Klin Wochenschr. 2005;117 Suppl 6:89-97. doi: 10.1007/s00508-005-0484-y.
4
The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.生物相容性碳酸氢盐腹膜透析液条件下透析液中癌抗原125浓度的变化及间皮细胞活力的维持。
Ren Fail. 2008;30(2):161-7. doi: 10.1080/08860220701808384.
5
Biocompatible dialysis fluids for peritoneal dialysis.用于腹膜透析的生物相容性透析液。
Cochrane Database Syst Rev. 2014 Mar 27(3):CD007554. doi: 10.1002/14651858.CD007554.pub2.
6
Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.碳酸氢盐/乳酸盐缓冲腹膜透析液在自动化腹膜透析中的生物相容性模式:一项前瞻性随机研究。
Nephrol Dial Transplant. 2004 Aug;19(8):2101-6. doi: 10.1093/ndt/gfh326. Epub 2004 Jun 22.
7
Advances in peritoneal dialysis: towards improved efficacy and safety.腹膜透析的进展:迈向更高的疗效与安全性
Blood Purif. 1998;16(1):1-14. doi: 10.1159/000014307.
8
BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].儿童生物相容性腹膜透析液中碳酸氢盐与乳酸盐缓冲剂比较的随机对照试验[国际标准随机对照试验编号:ISRCTN81137991]
BMC Nephrol. 2004 Oct 14;5:14. doi: 10.1186/1471-2369-5-14.
9
New technologies in peritoneal dialysis.腹膜透析的新技术
Clin J Am Soc Nephrol. 2007 May;2(3):576-80. doi: 10.2215/CJN.03331006. Epub 2007 Mar 21.
10
Peritoneal dialysis.腹膜透析
Lancet. 1999 Mar 6;353(9155):823-8. doi: 10.1016/s0140-6736(98)09410-0.

引用本文的文献

1
Clinical significance of serum glucose to lymphocyte ratio as a prognostic marker in peritoneal dialysis patients.血清葡萄糖与淋巴细胞比值作为腹膜透析患者预后标志物的临床意义。
Ren Fail. 2023 Dec;45(1):2224893. doi: 10.1080/0886022X.2023.2224893.
2
Oxidation State in Peritoneal Dialysis in Patients with Type 2 Diabetes Mellitus.2 型糖尿病患者腹膜透析中的氧化应激状态。
Int J Mol Sci. 2023 Jan 31;24(3):2669. doi: 10.3390/ijms24032669.
3
Oxidative Stress in Patients Undergoing Peritoneal Dialysis: A Current Review of the Literature.
腹膜透析患者的氧化应激:文献综述。
Oxid Med Cell Longev. 2017 Dec 27;2017:3494867. doi: 10.1155/2017/3494867. eCollection 2017.